GlassScriptPhysician profile
Joshua Benjamin Bacon
NPI 1396274551
$8,830.95
in general payments reported to CMS, 2019-2025
32 companies · $13.77 in 2025
The $13.77 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $276 · 2021: $2,599 · 2022: $2,586 · 2023: $2,426 · 2024: $929 · 2025: $13.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,369.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.50 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $989.32 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $824.42 | 2020-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $778.82 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $650.87 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $551.05 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Esperion Therapeutics, INC. | $432.60 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $390.65 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $309.02 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $298.82 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.08 | 2021-2024 | Jardiance, Ofev, Synjardy |
| Pfizer INC. | $266.26 | 2023-2024 | |
| Astellas Pharma US INC | $243.57 | 2022-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $203.54 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $182.99 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $157.31 | 2022 | |
| Abbott Laboratories | $130.93 | 2022-2024 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $127.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.86 | 2021-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $84.43 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $72.28 | 2022-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $70.92 | 2022-2023 | Seglentis, Livalo |
| Exact Sciences Corporation | $70.65 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $68.98 | 2023-2024 | Auvelity |
| Sumitomo Pharma America, INC. | $63.75 | 2023-2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $46.23 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $27.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.63 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.89 | 2021 | |
| Vyera Pharmaceuticals, LLC | $14.23 | 2021 | |
| Currax Pharmaceuticals LLC | $13.39 | 2023 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.